

# **$\beta_6$ -Integrin serves as a novel serum tumor marker for colorectal carcinoma**

Susan Bengs<sup>1</sup>, Eugenia Becker<sup>1</sup>, Philipp Busenhardt<sup>1</sup>, Marianne R. Spalinger<sup>1</sup>, Tina Raselli<sup>1</sup>, Stephanie Kasper<sup>1</sup>, Silvia Lang<sup>1</sup>, Kirstin Atrott<sup>1</sup>, Celine Mamie<sup>1</sup>, Stephan R. Vavricka<sup>1</sup>, Lotta von Boehmer<sup>2</sup>, Alexander Knuth<sup>3</sup>, Anne Tuomisto<sup>4,5</sup>, Markus J. Mäkinen<sup>4,5</sup>, Petr Hruz<sup>6</sup>, Matthias Turina<sup>7</sup>, Andreas Rickenbacher<sup>7</sup>, Henrik Petrowsky<sup>7</sup>, Achim Weber<sup>8</sup>, Pascal Frei<sup>9</sup>, Marcel Halama<sup>10</sup>, Gisli Jenkins<sup>11</sup>, Dean Sheppard<sup>12</sup>, Roland S. Croner<sup>13</sup>, Jan Christoph<sup>14</sup>, Nathalie Britzen-Laurent<sup>15</sup>, Elisabeth Naschberger<sup>15</sup>, Vera Schellerer<sup>15</sup>, Michael Stürzl<sup>15</sup>, Michael Fried<sup>1</sup>, Gerhard Rogler<sup>1,16</sup>, Michael Scharl<sup>1,16</sup>

<sup>1</sup>Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. <sup>2</sup>Department of Immunology, Stanford University, Stanford, USA. <sup>3</sup>National Center for Cancer Care & Research NCCCR, Hamad Medical Corporation, Doha, Qatar. <sup>4</sup>Cancer and Translational Medicine Research Unit, Department of Pathology, University of Oulu, Oulu, Finland. <sup>5</sup>Oulu University Hospital and Medical Research Center Oulu, Oulu, Finland. <sup>6</sup>Department of Gastroenterology, University Hospital, Basel, Basel, Switzerland. <sup>7</sup>Department of Visceral and Transplant Surgery, University and University Hospital Zurich, Zürich, Switzerland. <sup>8</sup>Department of Pathology, Institute of Surgical Pathology, University Hospital Zurich, Zurich, Switzerland. <sup>9</sup>Clinic for Gastroenterology Bethanien, Zürich, Switzerland. <sup>10</sup>Clinic for Gastroenterology Zurich-Fluntern, Zurich, Switzerland. <sup>11</sup>Faculty of Medicine & Health Sciences, University of Nottingham, Nottingham, UK. <sup>12</sup>Department of Medicine, Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, University of California, San Francisco, USA. <sup>13</sup>Department of Surgery, University Hospital Magdeburg, Magdeburg, Germany. <sup>14</sup>Chair of Medical Informatics, University of Erlangen-Nuremberg, Erlangen, Germany. <sup>15</sup>University Medical Center

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ijc.32137

Erlangen, Division of Molecular and Experimental Surgery, University Hospital  
Erlangen, Erlangen, Germany. <sup>16</sup>Zurich Center for Integrative Human Physiology,  
University of Zurich, Zurich, Switzerland.

Accepted Article

**Running title:** Beta-6-integrin as a novel tumor marker in colorectal cancer

**Financial support:** This work was supported by the Stiftung Experimentelle Biomedizin, the Swiss National Science Foundation [Grant No. 314730-146204, Grant No. 314730\_166381 and Grant No. CRSII3 154488/1], the Promedica Foundation, Chur, the Hartmann-Müller Foundation and the Foundation for Scientific Research at the University of Zurich (grants to M.Sc.) and grants from the German Research Foundation (DFG, RU2438 and SFB/TRR241) to M.St.

**Corresponding author:** Prof. Dr. med. Michael Scharl, Department of Gastroenterology and Hepatology, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland. Phone: +41 (0) 44 255 3419, Fax: +41 (0) 44 255 9497. E-mail: michael.Scharl@usz.ch

**Conflict of interest disclosure statement:** Dean Sheppard received funding from Biogen Idec, Pliant Therapeutics and own stocks in Pliant Therapeutics. Gisli Jenkins declares a potential financial conflict of interest with Biogen Idec, Boehringer Ingelheim, Galapagos, Galecto, GlaxoSmithKline, Heptares, Medimmune, Pliant Therapeutics, REDEX and Roche. The other authors have no potential conflicts of interest.

**Key Words:** Colorectal cancer, ITGB6, serum tumor marker, metastasis, surveillance, therapy response

**Research Article**

**Abbreviations:** CEA, carcinoembryonic antigen; CRC, colorectal cancer; ITGB6,  $\beta_6$ -integrin; mCRC, metastatic CRC.

## ABSTRACT

Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide and the need for novel biomarkers and therapeutic strategies to improve diagnosis and surveillance is obvious. This study aims to identify  $\beta$ 6-integrin (ITGB6) as a novel serum tumor marker for diagnosis, prognosis, and surveillance of CRC. ITGB6 serum levels were validated in retro- and prospective CRC patient cohorts. ITGB6 serum levels were analyzed by ELISA. Using an initial cohort of 60 CRC patients, we found that ITGB6 is present in the serum of CRC, but not in non-CRC control patients. A cut-off of  $\geq 2^{ng}/mL$  ITGB6 reveals 100% specificity for the presence of metastatic CRC. In an enlarged study cohort of 269 CRC patients, ITGB6 predicted the onset of metastatic disease and was associated with poor prognosis. Those data were confirmed in an independent, prospective cohort consisting of 40 CRC patients. To investigate whether ITGB6 can also be used for tumor surveillance, serum ITGB6-levels were assessed in 26 CRC patients, pre- and post-surgery, as well as during follow-up visits. After complete tumor resection, ITGB6 serum levels declined completely. During follow-up, a new rise in ITGB6 serum levels indicated tumor recurrence or the onset of new metastasis as confirmed by CT scan. ITGB6 was more accurate for prognosis of advanced CRC and for tumor surveillance as the established marker carcinoembryonic antigen (CEA). Our findings identify ITGB6 as a novel serum marker for diagnosis, prognosis, and surveillance of advanced CRC. This might essentially contribute to an optimized patient care.

## NOVELTY AND IMPACT

Our data demonstrated that ITGB6-levels in the serum of CRC patients can be used as a novel biomarker for diagnosis, prognosis, and tumor surveillance. A cut-off of  $\geq 2^{\text{ng}}/\text{mL}$  ITGB6 predicts metastatic disease and poor prognosis. ITGB6 serum levels indicate treatment response, tumor recurrence, and onset of new metastasis. Our findings suggest a novel approach for diagnosis and surveillance of patients with CRC and provide an important step towards personalized medicine in CRC patients.

## INTRODUCTION

Colorectal cancer (CRC) is the third most common malignancy and one of the leading causes of cancer-related deaths worldwide. Every fourth patient with CRC exhibits metastases at time of diagnosis and every second will develop metastasis during disease course(1). Easily accessible biomarkers, such as serum markers, are an important tool for optimizing patient care in patients with CRC. Such serum biomarkers should be ideally usable for diagnosis and surveillance of the disease. At present, carcinoembryonic antigen (CEA) is the clinical standard as CRC biomarker. However, it exhibits only a low sensitivity and specificity.

Previous studies suggested that  $\beta_6$ -integrin (ITGB6) may be involved in CRC pathogenesis(2-6). ITGB6 is exclusively expressed on epithelial cells (EC) during embryogenesis, and upregulated in adult EC during processes involving epithelial-to-mesenchymal transition (EMT), such as wound healing, fibrosis, and carcinogenesis(7,8). ITGB6 contributes to the activation of latent TGF $\beta$  and perpetuates TGF $\beta$ -mediated EMT(9,10), which is a key process during CRC progression and metastasis(11). In CRC cells, ITGB6 promotes its own expression in an autocrine manner and induces cell proliferation, chemo-resistance, cell migration, and invasiveness, but also inhibits apoptosis via its unique cytoplasmic tail, absent in other integrins(2,12-16).

The purpose of the present study, using retro- and prospectively collected patient cohorts, was to investigate, whether ITGB6 in serum might serve as a novel tumor marker for CRC patients. We hypothesized that ITGB6 in patients' serum might represent a novel marker for diagnosis, prognosis, as well as tumor surveillance in CRC patients. The identification of such a novel serum marker would be a great benefit for daily patient care, and represent a crucial step forward towards a personalized medicine approach for CRC patients.

## MATERIAL AND METHODS

**STUDY POPULATION.** Samples from CRC patients and healthy controls were recruited and collected at the University Hospital Zurich (Switzerland), the University Hospital Erlangen (Germany), the University Hospital Basel (Switzerland), the University of Oulu (Finland), and ProteoGenex Inc. (USA) between 06/2003 and 01/2017 (supplement methods and supplement tables 1, 3-5).

**ETHICAL CONSIDERATION.** The studies were approved by the Cantonal Ethics Committee of the Canton Zurich (Switzerland; Approval-No. EK-1755) and by the local ethics committees Erlangen (Germany; Approval-No. 3402; Ethikkommission der FAU) and Oulu (Finland), respectively. All participants were informed personally and provided written informed consent for this study. Patients' data were pseudonymized and all analyses were carried out in accordance with the Helsinki declaration.

**HUMAN ITGB6 AND CEA DETECTION.** Serum ITGB6-levels were measured using human ITGB6 ELISA kit (E92099Hu, USCN Life Science Inc., Wuhan; China) according to manufacturer's instructions. CEA serum levels were analyzed at the Institute of Clinical Chemistry at the University Hospital Zurich. Please see supplemental methods for more details.

**STATISTICAL ANALYSES.** Data are reported according to the remark criteria(17). Statistical analyses were performed using IBM SPSS statistics 22.0 and 23.0 (SPSS Inc., Chicago, IL; USA). Please see supplemental methods for more details.

## RESULTS

### PROOF-OF-CONCEPT VALIDATION OF BETA-6-INTEGRIN AS A SERUM MARKER FOR COLORECTAL CANCER

To explore whether ITGB6 is present in the serum of CRC patients, we first investigated serum ITGB6-levels in an initial retrospective study cohort including 60 CRC patients including all four UICC tumor stages and 19 healthy volunteers (**Cohort 1, Supplemental table 1**). Here, we found that ITGB6 was present in the serum of CRC patients, within a range between 0–10.203<sup>ng</sup>/<sub>mL</sub>. In contrast, serum ITGB6-levels of healthy volunteers were always 0<sup>ng</sup>/<sub>mL</sub> (**Fig. 1A**). We then performed receiver-operating-characteristic (ROC) analysis and determined an area under the curve (AUC) of 0.858±0.040 (95% CI 0.779–0.937;  $P=0.000003$ ; **Fig. 1B**). In the next step, we evaluated which cut-off value of ITGB6 serum level might be useful for daily clinical practice. We defined two cut-off values of either 0.1<sup>ng</sup>/<sub>mL</sub> and 2.0<sup>ng</sup>/<sub>mL</sub> ITGB6 concentration in the serum that both revealed 100% specificity and a sensitivity of 69.8% and 27.8%, respectively, for the presence of CRC overall (**Fig. 1B**). Beyond, we validated those observations in an independent, prospectively collected cohort consisting of 40 CRC patients featuring all four UICC tumor stages (**Cohort 2, Supplemental table 2**). Using this cohort 2, we were able to confirm our previous findings obtained using cohort 1 ( $P=0.000002$ ; **Fig. 1C**) that ITGB6 revealed an equally good performance with an AUC of 0.847±0.052 (95% CI 0.746–0.948;  $P=0.000026$ ; **Fig. 1D**).

In summary, these results suggest that ITGB6 is detectable in the serum of CRC patients and represents a feasible serum marker for the diagnosis of CRC.

### BETA-6-INTEGRIN AS A MARKER FOR DIAGNOSIS OF ADVANCED COLORECTAL CANCER

To understand whether serum ITGB6 concentrations also reflect tumor stages in



CRC patients, an enlarged cohort of 269 CRC patients was studied (**Cohort 3, Fig. 1E+F, Supplemental table 3**). Increased ITGB6 serum levels in CRC patients from cohort 3 significantly correlated with features of advanced CRC, such as presence of lymph node (LN) and distant organ metastases at time of blood draw (**Fig. 1E+F; Supplemental Fig. 1A–C+2A, Supplemental table 4**). Considering our predefined cut-off levels, we found that every second patient with an ITGB6 serum level  $\geq 0.1^{\text{ng/mL}}$  ITGB6 suffered from metastatic CRC (mCRC), however, all patients with a serum level  $\geq 2.0^{\text{ng/mL}}$  ITGB6 exhibited metastatic disease at time of blood draw (**Fig. 1E, Supplemental tables 4+5**).

We then analyzed the association of serum ITGB6-levels with TNM-classification at time of CRC diagnosis. The percentage of patients with tumor positive lymph nodes (N-status) and metastasis (M-status) at diagnosis increased with higher serum ITGB6-levels (**Supplemental Fig. 1A+B+2A, Supplemental tables 3+5**). In contrast, tumor infiltration (T-status) and differentiation (G-status) were not associated with ITGB6 serum levels (**Supplemental table 3**). However, an elevated lymph node ratio (LNR), defined as the ratio of positive mesenteric LN to the total number of resected mesenteric LN during surgery, directly correlated with increased ITGB6 serum levels (overall  $P=1.46 \times 10^{-7}$ ; **Fig. 1F, Supplemental tables 4+5**).

To examine ITGB6 protein expression and the cell type expressing ITGB6 in primary and metastatic CRC tissue, we analyzed 39 primary CRC and 23 mCRC from patients of cohort 3. As previously reported(18-20), we also found that ITGB6 was present in cells within the tumor, along the invasion front and in cells within the tumor stroma of primary CRC and metastasis (**Supplemental Fig. 3**). ITGB6 staining intensity correlated with the ITGB6 serum levels in primary CRC, but not in mCRC (**Supplemental Fig. 3A**). Notably, ITGB6 staining intensity decreased the further the distance from the primary CRC (**Supplemental Fig. 3B**)(20), but was to some extent

still present in microscopically normal appearing colon along the invasion front. CRC cells within liver, lung and LN metastasis revealed a strong staining intensity for ITGB6 independent from ITGB6 serum level (**Supplemental Fig. 3C–E**).

Interestingly, ITGB6 was not only present in the tumor cells of the primary CRC and mCRC as indicated by CDX2 co-staining (marker for intestinal epithelial cells), but also demonstrated a co-expression with either CD68 (marker for macrophage-lineage cells) or vimentin (VIM, marker for mesenchymal-like cells) within the tumor stroma (**Supplemental Fig. 4**).

To further investigate molecular differences between colon cancer tissue from patients with high vs. low serum ITGB6 level, we used colon cancer tissue samples and serum samples from a prospectively collected cohort of colon cancer patients (**Cohort 4, Supplemental table 6**). We analyzed ITGB6 mRNA levels in colon cancer tissues from 352 patients representing all four UICC tumor stages. We found that mRNA levels did not differ between UICC tumor stages (**Fig. 2A, Supplemental table 6**). However, analysis of ITGB6 serum levels in 40 patients from cohort 2 that were selected according to UICC stages out of the cohort 4 patients (cohort 2 is a subgroup of patients from cohort 4), revealed that ITGB6 serum levels increased with UICC tumor stage despite no obvious change in mRNA levels (**Fig. 2A+B, Supplemental table 6**).

Taken together, our data confirm on the one hand that ITGB6 is present in the serum and tumor tissue of CRC patients, and even more importantly, that serum ITGB6 concentrations represent a marker for advanced CRC.

#### **SERUM LEVELS OF BETA-6-INTEGRIN INDICATE PROGNOSIS IN PATIENTS WITH COLORECTAL CANCER**

We then examined the prognostic value of ITGB6 serum levels with respect to patient survival in cohort 3. We found that ITGB6 serum concentrations are correlated

with overall survival ( $r_s$  0.522,  $P=8.43 \times 10^{-19}$ ; **Fig. 2C**) in all subgroups of CRC patients (stage I–IV patients; **Supplemental Fig. 2B–E**). The 5-year survival rate was clearly lower in patients with serum concentrations  $\geq 2.0^{ng}/mL$  ITGB6 (mean survival  $2.6 \pm 1.5$  years; hazard ratio [HR] of 5.189, 95% CI 2.801–9.612;  $P=1.65 \times 10^{-7}$ ). In contrast, patients with lower ITGB6 serum levels, between  $0.1$ – $1.99^{ng}/mL$  ITGB6 displayed a HR of 2.524 (95% CI 1.463–4.355;  $P=0.001$ ) and a mean survival of  $4.6 \pm 2.4$  years (**Fig. 2D**, **Supplemental table 2**). Kaplan-Meier analysis confirmed that elevated ITGB6 serum levels were significantly associated with poor prognosis and a reduced survival rate ( $P=1.23 \times 10^{-8}$ ; **Fig. 2D**). Those observations might be due to the fact that all patients with  $\geq 2.0^{ng}/mL$  ITGB6 suffered from metastatic disease (**Fig. 2C**).

Subsequently, we performed a subgroup analysis of cohort 3 and investigated only CRC patients that underwent chemo-/radiotherapy before blood draw and categorized them according to their metastatic status and serum ITGB6-levels (**Fig. 2E**). Patients with no metastasis and low ITGB6 serum levels that underwent chemo-/radiotherapy treatment before blood draw revealed a significantly better survival ( $P=0.005$ ) compared to CRC patients with metastasis and high levels of ITGB6 (**Fig. 2E**). In general, these data indicate that serum levels of ITGB6 might predict the prognosis of CRC patients.

### BETA-6-INTEGRIN IMPROVES THE DIAGNOSIS OF ADVANCED CRC

Next, we compared serum ITGB6 levels with serum CEA levels (carcinoembryonic antigen; normal value  $< 5.0^{ug}/L$ ) in patients from cohort 3. We found a moderate correlation of serum levels of ITGB6 and CEA in CRC patients ( $r_s$  0.510,  $P=0.003$ ;

**Fig. 3A**). High serum CEA levels were associated with elevated ITGB6 serum levels. However, CEA serum levels were highly variable, ranging between  $1.2$ – $9,081.0^{ug}/L$  even in patients with mCRC, confirming that CEA is not optimal for reliable diagnosis of

advanced CRC. In contrast, patients with  $\geq 2.0^{\text{ng}}/\text{mL}$  ITGB6 displayed 100% mCRC, indicating a clearly higher accuracy for ITGB6 to delineate the presence of metastasis at time of blood draw than CEA (**Fig. 3A, Supplemental table 4**). A similar high accuracy for presence of metastasis was detected for  $\geq 0.1^{\text{ng}}/\text{mL}$  ITGB6 serum level in parallel with  $\geq 5.0^{\mu\text{g}}/\text{L}$  CEA serum level at time of blood draw. Our results indicate that ITGB6 serum concentrations together with CEA would refine the diagnosis of metastatic disease in CRC in clinical practice.

#### **BETA-6-INTEGRIN IN THE SERUM REPRESENTS A RELIABLE MARKER FOR TUMOR SURVEILLANCE IN CRC PATIENTS**

Next, we investigated whether ITGB6 serum levels can be used for tumor surveillance and monitoring of the disease course over time in CRC patients. To address this goal, we established a prospective patient cohort consisting of 26 CRC patients undergoing surgery due to CRC (**Cohort 5, Supplemental table 7**). Here, we studied ITGB6 serum concentrations directly pre-surgery (day -1 to -3) and post-surgery (day 2–6), as well as during follow-up visits (weeks 3–20) (**Fig. 3B**). Additionally, we analyzed the clinical standard marker CEA as a reference serum marker (**Fig. 3C**), to compare the accuracy of ITGB6 with CEA for tumor surveillance.

Almost no detectable ITGB6 serum concentrations were observed in CRC patients from cohort 5 without lymph node- or solid organ metastasis at all-time points of blood draw (**Fig. 3B, Supplemental table 7**). Five patients with LN metastases, but without distant metastases, revealed ITGB6 serum concentrations of 0.00–1.94<sup>ng</sup>/mL pre-surgery, which dropped to 0.00–0.07<sup>ng</sup>/mL post-surgery, including the follow-up visits of those patients, representing complete tumor resection. Interestingly, ITGB6 serum concentration increased to 1.40<sup>ng</sup>/mL in one patient, who was diagnosed with liver

metastases at a second follow-up visit (80 weeks after surgery). Of note, CEA levels did not show any increase at this time point (**Fig. 3C**).

In six patients with liver metastases, pre-surgery ITGB6-levels were between 0.05–1.98<sup>ng</sup>/<sub>mL</sub> (**Fig. 3B+E, Supplemental table 8**). Post-surgery, those patients also revealed lower levels of ITGB6 overall (0.06–1.21<sup>ng</sup>/<sub>mL</sub>). One of those patients underwent resection of the primary tumor and the liver metastases and ITGB6-levels declined after surgery (**Supplemental table 8**). Three patients exhibited a clear decline of ITGB6 serum levels after primary tumor resection, whereas two patients remained stable during adjuvant chemotherapy for the remaining liver metastases. However, in one patient, a significant increase during follow-up visit was observed, and the patients was then diagnosed with progression of the remaining liver metastases (**Fig. 3B+E**). While we detected a direct correlation between tumor resection resulting in a reduction of tumor load in the body and a decrease of ITGB6 serum levels, no such correlation was found for serum CEA levels in our patients (**Fig. 3C+F**). Moreover, while we found a moderate correlation between ITGB6 and CEA serum levels in the retrospective cohort, we found only a weak correlation in the follow-up cohort ( $r_s$  0.357,  $P=0.006$ ; **Fig. 3D**), implying that there is no direct correlation between ITGB6 and CEA during disease course and after resection of the primary tumor. In particular, while ITGB6 serum levels indicated the presence of mCRC, CEA serum levels were elevated without signs of any metastatic disease in those CRC patients. This was further defined by ROC curve analysis for CEA serum levels that showed only a fair AUC of  $0.761 \pm 0.068$  (95% CI 0.629–0.894;  $P=7.15 \times 10^{-4}$ ; **Fig. 3G**) to define metastatic disease. In comparison, serum levels of ITGB6 showed an excellent AUC of  $0.911 \pm 0.042$  (95% CI 0.828–0.944;  $P=1.02 \times 10^{-7}$ ; **Fig. 3G**) to identify metastatic disease in the same patient cohort.

These observations suggest that ITGB6 might serve as a serum biomarker for diagnosis and prognosis of metastatic CRC patients, and indicates tumor surveillance, relapse, and treatment response to surgery.

## DISCUSSION

Our findings suggest that serum ITGB6 concentration can be used as a biomarker for diagnosis, prognosis, and surveillance of CRC, especially for patients with advanced CRC. We were able to define two cut-off values for ITGB6 with 100% specificity, and a diagnostic sensitivity of 69.8% ( $0.1^{ng/mL}$ ) and 27.8% ( $2.0^{ng/mL}$ ), respectively, for the detection of CRC. Those observations were confirmed by analyzing ITGB6 serum levels in a separate and independent prospective CRC patient cohort, namely cohort 2.

Our data also suggested that ITGB6 in the serum can be used as a reliable marker for tumor surveillance. Here, elevated serum levels of ITGB6 clearly declined after successful tumor therapy and remained at very low or even undetectable levels as long as no tumor recurrence was detected. However, tumor progression or onset of new metastasis resulted in a rise in serum ITGB6 levels and correlated with the observed tumor load in those patients. In contrast, CEA serum concentrations of those patients were not directly related to treatment response. These findings demonstrated that ITGB6 might be superior to CEA serum levels for tumor surveillance and delineated the importance of serum ITGB6-levels for routinely tumor surveillance.

A limitation of our study is the relatively small number of patients in the prospective tumor surveillance part of the study. However, establishing such a prospective cohort and the respective analyses and read-outs would require a large number of patients and was therefore beyond the scope of this present proof-of-principle study. Nevertheless, our data already demonstrated the potential relevance of serum ITGB6 levels for tumor surveillance in CRC patients. A further limitation is that our study utilizes different patient cohorts what might make the studied patient collective heterogeneous. We cannot exclude some biases arising due to this heterogeneity. In particular, the years of recruitment span from 2003 and 2017, four hospitals and one private company. On the other hand, this can also be regarded as a strength of the study, since the results obtained by analyzing those different cohorts are

highly conserved and suggest that the observations made in this study are consistent and can be applied to the real life setting.

In summary, our findings provide evidence that ITGB6 can serve as a novel serum biomarker for diagnosis and prognosis of advanced CRC and as a marker for tumor surveillance, relapse, and treatment response. Herein, ITGB6 serum levels are clearly superior to ITGB6 tumor tissue levels(18). Those findings provide a crucial step towards a personalized medicine approach for the diagnosis and surveillance of patients with CRC. Further, ITGB6 serum level can be used for the detection of advanced CRC as well as for tumor surveillance via an easy blood (serum) test that seems to be superior to the current clinical standard CEA. In conclusion, our findings suggest that measuring serum levels of ITGB6 may be a novel and promising diagnostic strategy in the treatment of CRC patients and a critical step towards a personalized medicine approach.

## REFERENCES

1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut* **2017**;66(4):683-91 doi 10.1136/gutjnl-2015-310912.
2. Cantor DI, Cheruku HR, Nice EC, Baker MS. Integrin alphavbeta6 sets the stage for colorectal cancer metastasis. *Cancer Metastasis Rev* **2015**;34(4):715-34 doi 10.1007/s10555-015-9591-z.
3. Agrez MV, Bates RC, Mitchell D, Wilson N, Ferguson N, Anseline P, *et al.* Multiplicity of fibronectin-binding alpha V integrin receptors in colorectal cancer. *Br J Cancer* **1996**;73(7):887-92.
4. Morgan MR, Thomas GJ, Russell A, Hart IR, Marshall JF. The integrin cytoplasmic-tail motif EKQKVDLSTDC is sufficient to promote tumor cell invasion mediated by matrix metalloproteinase (MMP)-2 or MMP-9. *J Biol Chem* **2004**;279(25):26533-9 doi 10.1074/jbc.M401736200.
5. Yang GY, Xu KS, Pan ZQ, Zhang ZY, Mi YT, Wang JS, *et al.* Integrin alpha v beta 6 mediates the potential for colon cancer cells to colonize in and metastasize to the liver. *Cancer Sci* **2008**;99(5):879-87 doi 10.1111/j.1349-7006.2008.00762.x.
6. Cantor D, Slapetova I, Kan A, McQuade LR, Baker MS. Overexpression of alphavbeta6 integrin alters the colorectal cancer cell proteome in favor of elevated proliferation and a switching in cellular adhesion that increases invasion. *J Proteome Res* **2013**;12(6):2477-90 doi 10.1021/pr301099f.
7. Breuss JM, Gillett N, Lu L, Sheppard D, Pytela R. Restricted distribution of integrin beta 6 mRNA in primate epithelial tissues. *J Histochem Cytochem* **1993**;41(10):1521-7.
8. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, *et al.* Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. *J Cell Sci* **1995**;108 ( Pt 6):2241-51.
9. Jenkins RG, Su X, Su G, Scotton CJ, Camerer E, Laurent GJ, *et al.* Ligation of protease-activated receptor 1 enhances alpha(v)beta6 integrin-dependent TGF-beta activation and promotes acute lung injury. *J Clin Invest* **2006**;116(6):1606-14 doi 10.1172/JCI27183.
10. Annes JP, Chen Y, Munger JS, Rifkin DB. Integrin alphaVbeta6-mediated activation of latent TGF-beta requires the latent TGF-beta binding protein-1. *J Cell Biol* **2004**;165(5):723-34 doi 10.1083/jcb.200312172.
11. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. *Oncogene* **2005**;24(37):5764-74 doi 1208927 [pii] 10.1038/sj.onc.1208927.
12. Niu J, Gu X, Ahmed N, Andrews S, Turton J, Bates R, *et al.* The alphaVbeta6 integrin regulates its own expression with cell crowding: implications for tumour progression. *Int J Cancer* **2001**;92(1):40-8.
13. Agrez M, Chen A, Cone RI, Pytela R, Sheppard D. The alpha v beta 6 integrin promotes proliferation of colon carcinoma cells through a unique region of the beta 6 cytoplasmic domain. *J Cell Biol* **1994**;127(2):547-56.
14. Ahmed N, Niu J, Dorahy DJ, Gu X, Andrews S, Meldrum CJ, *et al.* Direct integrin alphavbeta6-ERK binding: implications for tumour growth. *Oncogene* **2002**;21(9):1370-80 doi 10.1038/sj.onc.1205286.



15. Liu S, Wang J, Niu W, Liu E, Wang J, Peng C, *et al.* The beta6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer. *Cancer Lett* **2013**;328(2):325-34 doi 10.1016/j.canlet.2012.10.004.
16. Zhao-Yang Z, Ke-Sen X, Qing-Si H, Wei-Bo N, Jia-Yong W, Yue-Tang M, *et al.* Signaling and regulatory mechanisms of integrin alphavbeta6 on the apoptosis of colon cancer cells. *Cancer Lett* **2008**;266(2):209-15 doi 10.1016/j.canlet.2008.02.054.
17. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, *et al.* REporting recommendations for tumor MARKer prognostic studies (REMARK). *Nat Clin Pract Oncol* **2005**;2(8):416-22.
18. Bates RC, Bellovin DI, Brown C, Maynard E, Wu B, Kawakatsu H, *et al.* Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma. *J Clin Invest* **2005**;115(2):339-47 doi 10.1172/JCI23183.
19. Ahn SB, Mohamedali A, Chan C, Fletcher J, Kwun SY, Clarke C, *et al.* Correlations between integrin alphanubeta6 expression and clinico-pathological features in stage B and stage C rectal cancer. *PLoS One* **2014**;9(5):e97248 doi 10.1371/journal.pone.0097248.
20. Peng C, Gao H, Niu Z, Wang B, Tan Z, Niu W, *et al.* Integrin alphavbeta6 and transcriptional factor Ets-1 act as prognostic indicators in colorectal cancer. *Cell Biosci* **2014**;4(1):53 doi 10.1186/2045-3701-4-53.

## FIGURE LEGENDS

### Figure 1 Validation of ITGB6 as a possible serum marker for colorectal cancer (CRC).

(A) Serum levels of ITGB6 was assessed in a retrospective study cohort, *cohort 1*, of 60 CRC patients ( $n=60$ ) and 19 healthy volunteers ( $n=19$ ). (B) ROC curve was applied to reveal a good accuracy of ITGB6 to predict the presence of CRC, and reveals two cut-off values at  $0.1^{ng/mL}$  and  $2.0^{ng/mL}$  ITGB6. (C, D) In a prospective and independent serum cohort of 40 CRC patients ( $n=40$ , *cohort 2*) and 19 healthy volunteers ( $n=19$ ), ITGB6 serum levels were analyzed, and the ROC-curve applied, confirming the good performance of ITGB6 to predict CRC in those patients. (A, C) Mann-Whitney-U Exact Sig. 2-tailed test was performed. AUC (area under the curve); CI (confidence interval); CRC (colorectal cancer patients); Ctrl (healthy volunteers); ROC curve (receiver-operating-characteristic curve). \*\*\*  $P < 0.001$ .

In an enlarged serum cohort of 269 CRC patients ( $n=269$ , *cohort 3*), serum levels of ITGB6 were assessed (E+F). The two cut-off values at  $0.1^{ng/mL}$  and  $2.0^{ng/mL}$  ITGB6 compared with the disease severity and disease characteristics of these patients. (E) Classification of ITGB6 cut-off values according to the metastatic disease of CRC patients at time of blood draw ( $n=264$ ). (F) Two-dimensional scatterplot depicts serum levels of ITGB6 in relation to the lymph node ratio (LNR  $n=250$ ) of each patient, and according to their metastatic disease. In (E) Mann-Whitney-U Exact Sig. 2-tailed, and (F) Fisher's Exact Sig. 2-tailed test were performed. In (E) data are shown as means  $ITGB6 \pm SD$ . (F) Red lines indicating ITGB6 cut-off values at  $0.1^{ng/mL}$  and  $2.0^{ng/mL}$ ; black lines indicating LNR at 0.125, 0.263 and 0.500. <sup>a</sup> (Missing data); LNR (lymph node ratio); Met(-) (patients without metastasis); Met(+) (patients with metastasis); N (Percentage according to total N within each group);  $r_s$  (Spearman's rho correlation); SD (standard deviation). \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ .

### Figure 2 ITGB6 mRNA expression in colon cancer tissue and prognostic value of serum ITGB6-levels for patients with CRC.

(A) mRNA analysis for ITGB6 was performed using primary colon cancer tissue from patients with UICC stage I-IV tumors ( $n=352$ , *cohort 4*). (B) Serum levels of ITGB6 was assessed in a prospective study cohort of 40 CRC patients (*cohort 2*, a subgroup of *cohort 4*) and is depicted according to UICC tumor stages

I–IV. (C) Two-dimensional scatterplots depict serum ITGB6-levels in relation to the overall survival ( $n=249$ , cohort 3) from each CRC patient, and according to their metastatic disease. (D) Survival of CRC patients ( $n=141$ , cohort 3) is plotted according to ITGB6. The HR was calculated with the Cox regression according to the ITGB6 cut-off values of  $0.1^{ng/mL}$  and  $2.0^{ng/mL}$  ( $n=141$ ). (E) Survival rates of patients that underwent chemo and or radiotherapy before blood draw, were plotted according to the metastatic disease ( $n=60$ , subgroup of cohort 3). (C) Spearman's rho correlation ( $r_s$ ) Sig. 2-tailed test, and (D and E) Kaplan-Meier estimation was performed and plotted according to the ITGB6 cut-off ranges,  $\leq 0.1^{ng/mL}$ ,  $0.1-2.0^{ng/mL}$  and  $\geq 2.0^{ng/mL}$ , respectively. CRC patients defined as an event dies during 12-years follow-up and survived CRC patients were defined as censored cases. (C) Red lines indicating ITGB6 cut-off values at  $0.1^{ng/mL}$  and  $2.0^{ng/mL}$ ; black line indicates 5-year survival. HR (hazard ratio); Met(-) (patients without metastasis); Met(+) (patients with metastasis);  $r_s$  (Spearman's rho correlation); SD (standard deviation).

**Figure 3 Serum ITGB6-levels represents an improved diagnostic performance compared to CEA.** (A and D) Two-dimensional scatterplots depict ITGB6 serum levels in relation to serum levels of CEA from each CRC patient according to their metastatic disease, of (A) cohort 3 ( $n=32$ ), and (D) the follow-up serum cohort ( $n=19$ , cohort 5). Time course of ITGB6 (B,  $n=26$ ; and E,  $n=6$ ) and CEA (C,  $n=19$ ; and F,  $n=4$ ) serum levels from each CRC patient from cohort 5, directly pre-surgery (day -1 to -3), post-surgery (day 2–6), as well as during follow-up visits (I: weeks 3–20; II: week 80), and according to their metastatic disease (LNM(-)Met(-),  $n=15$ ; LNM(-)Met(+),  $n=5$ ; LNM(+)Met(+),  $n=6$ ). (G) To compare the diagnostic performance of ITGB6 and CEA to detect the presence of metastatic CRC, ROC curve was applied for serum ITGB6- and CEA-levels ( $n=25$ ). (A and D) Spearman's rho correlation ( $r_s$ ) Sig. 2-tailed test was applied. (A and D) Red lines indicating ITGB6 cut-off values at  $0.1^{ng/mL}$  and  $2.0^{ng/mL}$ ; black line indicates CEA cut-off value at  $5.0^{ug/L}$ . AUC (area under the curve); CI (confidence interval); CEA (carcinoembryonic antigen); CRLM (colorectal cancer metastasis in the liver); LNM(-) (without lymph node metastasis); LNM(+) (with mesenteric lymph node metastasis); Met(-) (patients without metastasis); Met(+) (patients with metastasis); ROC curve (receiver-operating-characteristic curve);  $r_s$  (Spearman's rho correlation).

## **SUPPLEMENTAL TABLES**

### **Supplemental table 1**

***Cohort 1:*** Demographic and clinico-pathological features of the initial ITGB6 serum cohort.

### **Supplemental table 2**

***Cohort 2:*** Demographic and clinico-pathological features of the independent, prospective ITGB6 serum cohort.

### **Supplemental table 3**

***Cohort 3:*** Demographic and clinico-pathological features of the enlarged ITGB6 serum cohort.

### **Supplemental table 4**

***Cohort 3:*** Sub grouped analyses of adverse occurrences of clinico-pathological features according to ITGB6 cut-off values in CRC patients.

### **Supplemental table 5**

***Cohort 3:*** Descriptive statistic of TNM status and LNR of the CRC patients.

### **Supplemental table 6**

***Cohort 4:*** Demographic and clinico-pathological features of the tumor tissue cohort.

### **Supplemental table 7**

***Cohort 5:*** Demographic and clinico-pathological features of the ITGB6 follow-up serum cohort.

**Supplemental table 8**

***Cohort 5: Survival and single values of ITGB6 and CEA after blood draw, pre-, post-surgery, and during follow-up visit, of CRC patients with mCRC.***

Accepted Article

## SUPPLEMENTAL FIGURES

**Supplemental Figure 1 Serum ITGB6-levels in correlation to features for advanced CRC.** Serum levels of ITGB6 was assessed in a retrospective study cohort, *cohort 3*, and ROC curve was applied to define the correlation of ITGB6 to predict (A) metastasis ( $n=264$ ) and (B) a LNR  $\geq 0.125$  ( $n=250$ ), (C) TNM-classification at time of CRC diagnosis in correlation to serum ITGB6-levels (T-status,  $n=262$ ; N-status,  $n=263$ ; M-status,  $n=267$ ; G-status,  $n=79$ ). In C) Mann-Whitney-U Exact Sig. 2-tailed, and C) Fisher's Exact Sig. 2-tailed test were performed. \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ .

**Supplemental Figure 2 Classification of ITGB6 according to the UICC staging.** Serum ITGB6-levels were assessed for each CRC patient (*cohort 3*), and listed in accordance to the (A) UICC staging at diagnosis ( $n=263$ ), and during disease course until time point of blood drawing ( $n=262$ ). (B–E) Survival rates of CRC patients according to their UICC stages (I,  $n=27$  (B); II,  $n=62$  (C); III,  $n=16$  (D); IV,  $n=42$  (E)) were plotted in dependency to the ITGB6 cut-off ranges, respectively. (A) Data are shown as means  $ITGB6 \pm SD$ . <sup>a</sup> (Missing data); N (Percentage according to total N within each group); SD (standard deviation); (B–E) Kaplan-Meier estimation was performed. Survival of CRC patients was plotted according to the ITGB6 cut-off ranges ( $\leq 0.1^{ng/mL}$ ,  $0.1-2.0^{ng/mL}$  and  $\geq 2.0^{ng/mL}$ , as well as to the UICC stage, respectively).

**Supplemental Figure 3 ITGB6 protein expression in CRC primary tumor and CRC metastasis.** (A and B) Immunohistochemistry (IHC) for ITGB6 was performed using primary tumor CRC tissue ( $n=39$ ), and tissue from (C) liver metastasis (CRLM,  $n=12$ ), (D) lung metastasis (CRPM,  $n=6$ ), and (E) lymph node metastasis (LNM,  $n=5$ ) of a subgroup from *cohort 3*. (A, C–E) Black arrows highlight brown cells that are stained for ITGB6. (B) Gradual brown arrow indicates the decrease of ITGB6-staining intensity with increasing distance to the tumor. Representative pictures were acquired with 50-fold (A–E) and 400-fold magnification (A, C–E). Black bar indicates 100  $\mu m$ . IHC (Immunohistochemistry); N (normal appearing tissue); T (tumor tissue).

**Supplemental Figure 4 Immunohistochemical co-staining of ITGB6, CDX2, CD68 or vimentin in primary tumor and CRC metastasis.** (A–C) Immunohistochemistry (IHC) of ITGB6 (brown stain) together with either CDX2 (marker for intestinal epithelial cells; upper panel), CD68 (marker for macrophage-lineage cells; middle panel) or vimentin (VIM, marker for mesenchymal-like cells; low panel) (purple stainings, respectively) were performed using tissue samples of CRC primary tumor (A) and CRC metastasis in (B) lung (CRPM) and (C) lymph nodes (LNM) of a subgroup from *cohort 3*. Arrows point to double-positive cells. No immunostaining was detected in (D) the ITGB6 IgG-isotope control and (E and F) in the secondary antibody control in primary CRC (D and E) and (C) in CRLM. Representative images were acquired with 50-fold (A–F), 200-fold, or 400-fold (A–C) magnification. Black bar indicates 100  $\mu$ m.

Figure








Figure 2



Figure



## Novelty & Impact Statement:

While serum biomarkers are ideal tools for colorectal cancer (CRC) detection, the identification of a marker with both high sensitivity and high specificity has proven challenging. Here, the authors investigated  $\beta$ 6-integrin (ITGB6), a molecule upregulated in association with epithelial-to-mesenchymal transition activities, such as wound healing and carcinogenesis, for its biomarker potential in CRC. In patients, ITGB6 serum levels were significantly associated with CRC diagnosis and prognosis. A cut-off of  $\geq 2$  ng/mL ITGB6 reliably predicted metastatic disease and poor CRC prognosis. The findings suggest that employing ITGB6 as a serum biomarker could greatly aid diagnosis and tumor surveillance in CRC patients.

Accepted Article